Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 77, Issue 5-6, 2007, Pages 309-318

  Al Turkmani, M Rabie ^a   Freedman, Steven D ^b   Laposata, Michael ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; FATTY ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; OMEGA 3 FATTY ACID; PLACEBO; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; CLINICAL TRIAL; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; GENE MUTATION; HUMAN; INFLAMMATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ARACHIDONIC ACID; CYSTIC FIBROSIS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS; FATTY ACIDS, OMEGA-3; HUMANS; LINOLEIC ACID; PHOSPHOLIPIDS;

EID: 36649003127     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2007.10.009     Document Type: Article

References (69)

1. Howell L.D., Borchardt R., Kole J., Kaz A.M., Randak C., and Cohn J.A. Protein kinase A regulates ATP hydrolysis and dimerization by a CFTR (cystic fibrosis transmembrane conductance regulator) domain. Biochem. J. 378 (2004) 151-159
2. Moss R.B. New approaches to cystic fibrosis. Hosp. Pract. (Off. Ed.) 36 (2001) 25-27 31-32, 35-37
3. Ciabattoni G., Davi G., Collura M., Iapichino L., Pardo F., Ganci A., Romagnoli R., Maclouf J., and Patrono C. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am. J. Respir. Crit. Care Med. 162 (2000) 1195-1201
4. Kube D., Sontich U., Fletcher D., and Davis P.B. Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am. J. Physiol. Lung Cell. Mol. Physiol. 280 (2001) L493-L502
5. Balough K., McCubbin M., Weinberger M., Smits W., Ahrens R., and Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr. Pulmonol. 20 (1995) 63-70
6. Hubeau C., Puchelle E., and Gaillard D. Distinct pattern of immune cell population in the lung of human fetuses with cystic fibrosis. J. Allergy Clin. Immunol. 108 (2001) 524-529
7. Venkatakrishnan A., Stecenko A.A., King G., Blackwell T.R., Brigham K.L., Christman J.W., and Blackwell T.S. Exaggerated activation of nuclear factor-kappa B and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 23 (2000) 396-403
8. Reynders V., Loitsch S., Steinhauer C., Wagner T., Steinhilber D., and Bargon J. Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes. Respir. Res. 7 (2006) 104
9. Hauber H.P., Tulic M.K., Tsicopoulos A., Wallaert B., Olivenstein R., Daigneault P., and Hamid Q. Toll-like receptors 4 and 2 expression in the bronchial mucosa of patients with cystic fibrosis. Can. Respir. J. 12 (2005) 13-18
10. Karp C.L., Flick L.M., Park K.W., Softic S., Greer T.M., Keledjian R., Yang R., Uddin J., Guggino W.B., Atabani S.F., Belkaid Y., Xu Y., Whitsett J.A., Accurso F.J., Wills-Karp M., and Petasis N.A. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5 (2004) 388-392
11. Wang L., and Freedman S.D. Laboratory tests for the diagnosis of cystic fibrosis. Am. J. Clin. Pathol. 117 Suppl. (2002) S109-S115
12. O'Sullivan B.P., Linden M.D., Frelinger III A.L., Barnard M.R., Spencer-Manzon M., Morris J.E., Salem R.O., Laposata M., and Michelson A.D. Platelet activation in cystic fibrosis. Blood 105 (2005) 4635-4641
13. Raper N.R., Cronin F.J., and Exler J. Omega-3 fatty acid content of the US food supply. J. Am. Coll. Nutr. 11 (1992) 304-308
14. Simopoulos A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother. 56 (2002) 365-379
15. Demar Jr. J.C., Ma K., Chang L., Bell J.M., and Rapoport S.I. Alpha-linolenic acid does not contribute appreciably to docosahexaenoic acid within brain phospholipids of adult rats fed a diet enriched in docosahexaenoic acid. J. Neurochem. 94 (2005) 1063-1076
16. Hubbard V.S., Dunn G.D., and di Sant'Agnese P.A. Abnormal fatty-acid composition of plasma-lipids in cystic fibrosis. A primary or a secondary defect?. Lancet 2 (1977) 1302-1304
17. Gibson R.A., Teubner J.K., Haines K., Cooper D.M., and Davidson G.P. Relationships between pulmonary function and plasma fatty acid levels in cystic fibrosis patients. J. Pediatr. Gastroenterol. Nutr. 5 (1986) 408-415
18. Christophe A.B., Warwick W.J., and Holman R.T. Serum fatty acid profiles in cystic fibrosis patients and their parents. Lipids 29 (1994) 569-575
19. Lloyd-Still J.D., Johnson S.B., and Holman R.T. Essential fatty acid status and fluidity of plasma phospholipids in cystic fibrosis infants. Am. J. Clin. Nutr. 54 (1991) 1029-1035
20. Lepage G., Levy E., Ronco N., Smith L., Galeano N., and Roy C.C. Direct transesterification of plasma fatty acids for the diagnosis of essential fatty acid deficiency in cystic fibrosis. J. Lipid Res. 30 (1989) 1483-1490
21. Rogiers V., Vercruysse A., Dab I., and Baran D. Abnormal fatty acid pattern of the plasma cholesterol ester fraction in cystic fibrosis patients with and without pancreatic insufficiency. Eur. J. Pediatr. 141 (1983) 39-42
22. Freedman S.D., Blanco P.G., Zaman M.M., Shea J.C., Ollero M., Hopper I.K., Weed D.A., Gelrud A., Regan M.M., Laposata M., Alvarez J.G., and O'Sullivan B.P. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 350 (2004) 560-569
23. Farrell P.M., Mischler E.H., Engle M.J., Brown D.J., and Lau S.M. Fatty acid abnormalities in cystic fibrosis. Pediatr. Res. 19 (1985) 104-109
24. Bhura-Bandali F.N., Suh M., Man S.F., and Clandinin M.T. The deltaF508 mutation in the cystic fibrosis transmembrane conductance regulator alters control of essential fatty acid utilization in epithelial cells. J. Nutr. 130 (2000) 2870-2875
25. Kang J.X., Man S.F., Brown N.E., Labrecque P.A., and Clandinin M.T. The chloride channel blocker anthracene 9-carboxylate inhibits fatty acid incorporation into phospholipid in cultured human airway epithelial cells. Biochem. J. 285 Part 3 (1992) 725-729
26. Thompson G.N. Relationships between essential fatty acid levels, pulmonary function and fat absorption in pre-adolescent cystic fibrosis children with good clinical scores. Eur. J. Pediatr. 148 (1989) 327-329
27. Strandvik B., Gronowitz E., Enlund F., Martinsson T., and Wahlstrom J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J. Pediatr. 139 (2001) 650-655
28. Roulet M., Frascarolo P., Rappaz I., and Pilet M. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur. J. Pediatr. 156 (1997) 952-956
29. Christophe A., Robberecht E., De Baets F., and Franckx H. Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis. Ann. Nutr. Metab. 36 (1992) 304-312
30. Freedman S.D., Katz M.H., Parker E.M., Laposata M., Urman M.Y., and Alvarez J.G. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc. Natl. Acad. Sci. USA 96 (1999) 13995-14000
31. Dombrowsky H., Clark G.T., Rau G.A., Bernhard W., and Postle A.D. Molecular species compositions of lung and pancreas phospholipids in the cftr(tm1HGU/tm1HGU) cystic fibrosis mouse. Pediatr. Res. 53 (2003) 447-454
32. Davidson D.J., and Rolfe M. Mouse models of cystic fibrosis. Trends Genet. 17 (2001) S29-S37
33. Gilljam H., Strandvik B., Ellin A., and Wiman L.G. Increased mole fraction of arachidonic acid in bronchial phospholipids in patients with cystic fibrosis. Scand. J. Clin. Lab. Invest. 46 (1986) 511-518
34. Balsinde J., Winstead M.V., and Dennis E.A. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett. 531 (2002) 2-6
35. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000) 145-182
36. Carlstedt-Duke J., Bronnegard M., and Strandvik B. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc. Natl. Acad. Sci. USA 83 (1986) 9202-9206
37. 2+-induced arachidonic acid release by epithelial cells. DNA Cell Biol. 16 (1997) 749-759
38. -/- knockout mice. Metabolism 55 (2006) 1192-1200
39. Ulane M.M., Butler J.D., Peri A., Miele L., Ulane R.E., and Hubbard V.S. Cystic fibrosis and phosphatidylcholine biosynthesis. Clin. Chim. Acta 230 (1994) 109-116
40. White N.M., Jiang D., Burgess J.D., Bederman I.R., Previs S.F., and Kelley T.J. Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 292 (2007) L476-L486
41. Sprecher H. Biochemistry of essential fatty acids. Prog. Lipid Res. 20 (1981) 13-22
42. Craig-Schmidt M.C., Faircloth S.A., Teer P.A., Weete J.D., and Wu C.Y. The essential fatty acid deficient chicken as a model for cystic fibrosis. Am. J. Clin. Nutr. 44 (1986) 816-824
43. Harper T.B., Chase H.P., Henson J., and Henson P.M. Essential fatty acid deficiency in the rabbit as a model of nutritional impairment in cystic fibrosis. In vitro and in vivo effects on lung defense mechanisms. Am. Rev. Respir. Dis. 126 (1982) 540-547
44. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., and Moussignac R.L. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196 (2002) 1025-1037
45. Linsdell P. Inhibition of cystic fibrosis transmembrane conductance regulator chloride channel currents by arachidonic acid. Can. J. Physiol. Pharmacol. 78 (2000) 490-499
46. Li Y., Wang W., Parker W., and Clancy J.P. Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia. Am. J. Resp. Cell Mol. Biol. 34 (2006) 600-608
47. Sampath H., and Ntambi J.M. Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu. Rev. Nutr. 25 (2005) 317-340
48. Stewart B., Zabner J., Shuber A.P., Welsh M.J., and McCray Jr. P.B. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am. J. Respir. Crit. Care Med. 151 (1995) 899-903
49. Stern R.C. The diagnosis of cystic fibrosis. N. Engl. J. Med. 336 (1997) 487-491
50. Batal I., Ericsoussi M.B., Cluette-Brown J.E., O'Sullivan B.P., Freedman S.D., Savaille J.E., and Laposata M. Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis. Clin. Chem. 53 (2007) 78-84
51. Konstan M.W., Byard P.J., Hoppel C.L., and Davis P.B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N. Engl. J. Med. 332 (1995) 848-854
52. Wilschanski M., Yahav Y., Yaacov Y., Blau H., Bentur L., Rivlin J., Aviram M., Bdolah-Abram T., Bebok Z., Shushi L., Kerem B., and Kerem E. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349 (2003) 1433-1441
53. Horrocks L.A., and Yeo Y.K. Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res. 40 (1999) 211-225
54. Blanco P.G., Freedman S.D., Lopez M.C., Ollero M., Comen E., Laposata M., and Alvarez J.G. Oral docosahexaenoic acid given to pregnant mice increases the amount of surfactant in lung and amniotic fluid in preterm fetuses. Am. J. Obstet. Gynecol. 190 (2004) 1369-1374
55. Parker E.M., O'Sullivan B.P., Shea J.C., Regan M.M., and Freedman S.D. Survey of breast-feeding practices and outcomes in the cystic fibrosis population. Pediatr. Pulmonol. 37 (2004) 362-367
56. Henderson Jr. W.R., Astley S.J., McCready M.M., Kushmerick P., Casey S., Becker J.W., and Ramsey B.W. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J. Pediatr. 124 (1994) 400-408
57. De Vizia B., Raia V., Spano C., Pavlidis C., Coruzzo A., and Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J. Parenter. Enteral Nutr. 27 (2003) 52-57
58. Mori T.A., Burke V., Puddey I.B., Watts G.F., O'Neal D.N., Best J.D., and Beilin L.J. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am. J. Clin. Nutr. 71 (2000) 1085-1094
59. Mori T.A., and Woodman R.J. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr. Opin. Clin. Nutr. Metab. Care 9 (2006) 95-104
60. Peet M., and Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 65 (2005) 1051-1059
61. M.R. Al-Turkmani., Ph.D. Thesis, Northeastern University, 2007, 25pp.
62. Lawrence R.H., and Sorrell T.C. Eicosapentaenoic acid modulates neutrophil leukotriene B4 receptor expression in cystic fibrosis. Clin. Exp. Immunol. 98 (1994) 12-16
63. Kurlandsky L.E., Bennink M.R., Webb P.M., Ulrich P.J., and Baer L.J. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr. Pulmonol. 18 (1994) 211-217
64. Clandinin M.T., Zuberbuhler P., Brown N.E., Kielo E.S., and Goh Y.K. Fatty acid pool size in plasma lipoprotein fractions of cystic fibrosis patients. Am. J. Clin. Nutr. 62 (1995) 1268-1275
65. Katz D.P., Manner T., Furst P., and Askanazi J. The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. Nutrition 12 (1996) 334-339
66. Thies N.H. The effect of 12 months' treatment with eicosapentaenoic acid in five children with cystic fibrosis. J. Paediatr. Child Health 33 (1997) 349-351
67. Panchaud A., Sauty A., Kernen Y., Decosterd L.A., Buclin T., Boulat O., Hug C., Pilet M., and Roulet M. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin. Nutr. (2005)
68. Lloyd-Still J.D., Powers C.A., Hoffman D.R., Boyd-Trull K., Lester L.A., Benisek D.C., and Arterburn L.M. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 22 (2006) 36-46
69. Jumpsen J.A., Brown N.E., Thomson A.B., Paul Man S.F., Goh Y.K., Ma D., and Clandinin M.T. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J. Cyst. Fibros. 5 (2006) 77-84